TG Therapeutics (NASDAQ:TGTX) Trading 9.5% Higher - Time to Buy?

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) rose 9.5% on Friday . The company traded as high as $39.94 and last traded at $40.57. Approximately 1,348,486 shares were traded during trading, a decline of 55% from the average daily volume of 2,977,866 shares. The stock had previously closed at $37.06.

Wall Street Analyst Weigh In

TGTX has been the subject of a number of analyst reports. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Trading Down 2.9 %

The firm has a market capitalization of $6.26 billion, a PE ratio of -398.74 and a beta of 2.30. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a 50 day simple moving average of $32.12 and a 200 day simple moving average of $29.21.

Remove Ads

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.50% of the company's stock.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after purchasing an additional 209,190 shares in the last quarter. State Street Corp raised its holdings in TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after acquiring an additional 2,398,015 shares during the period. Soleus Capital Management L.P. raised its holdings in TG Therapeutics by 5.8% during the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after acquiring an additional 146,702 shares during the period. Clearbridge Investments LLC bought a new stake in TG Therapeutics during the fourth quarter valued at about $55,237,000. Finally, Northern Trust Corp raised its holdings in TG Therapeutics by 8.6% during the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after acquiring an additional 120,785 shares during the period. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.